Jasper Therapeutics (JSPRW) Competitors $0.10 -0.01 (-11.56%) As of 10/24/2025 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock JSPRW vs. ATNFW, LBPSW, AIMDW, ALVOW, ACABW, BFRIW, BTMDW, BCTXW, CALA, and CELUWShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), biote (BTMDW), BriaCell Therapeutics (BCTXW), Calithera Biosciences (CALA), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors 180 Life Sciences 4D pharma Ainos Alvotech Atlantic Coastal Acquisition Corp. II Biofrontera biote BriaCell Therapeutics Calithera Biosciences Celularity 180 Life Sciences (NASDAQ:ATNFW) and Jasper Therapeutics (NASDAQ:JSPRW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Does the media favor ATNFW or JSPRW? In the previous week, Jasper Therapeutics had 1 more articles in the media than 180 Life Sciences. MarketBeat recorded 1 mentions for Jasper Therapeutics and 0 mentions for 180 Life Sciences. Jasper Therapeutics' average media sentiment score of 1.91 beat 180 Life Sciences' score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 180 Life Sciences Neutral Jasper Therapeutics Very Positive Is ATNFW or JSPRW more profitable? Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A N/A N/A Jasper Therapeutics N/A N/A N/A Which has better valuation & earnings, ATNFW or JSPRW? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/AN/AN/AN/AJasper TherapeuticsN/AN/AN/AN/AN/A SummaryJasper Therapeutics beats 180 Life Sciences on 2 of the 2 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPRW and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPRW vs. The Competition Export to ExcelMetricJasper TherapeuticsBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket CapN/A$219.36M$6.25B$10.65BDividend YieldN/A3.81%5.72%4.82%P/E RatioN/A3.2830.8930.59Price / SalesN/A5,399.00562.35176.22Price / CashN/A13.1937.0861.44Price / BookN/A90.1312.056.61Net IncomeN/A-$90.99M$3.33B$277.10M7 Day PerformanceN/A0.20%1.88%2.55%1 Month PerformanceN/A5.26%7.70%3.77%1 Year Performance-52.31%495.26%56.33%33.05% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRWJasper TherapeuticsN/A$0.10-11.6%N/A-51.9%$0.00N/A0.0020Positive NewsGap DownATNFW180 Life SciencesN/A$0.05-9.7%N/A+329.4%$0.00N/A0.007LBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAIMDWAinosN/A$0.19-0.9%N/AN/A$0.00$110.87K0.0040Positive NewsGap UpALVOWAlvotechN/A$1.71+11.8%N/A-39.1%$0.00$560.10M0.004Positive NewsGap UpACABWAtlantic Coastal Acquisition Corp. IIN/A$0.03-7.4%N/A-47.8%$0.00N/A0.0015BFRIWBiofronteraN/A$0.10+2.9%N/A+223.7%$0.00$39.19M0.0070Positive NewsBTMDWbioteN/A$0.01+6.3%N/AN/A$0.00$199.07M0.00N/AGap DownBCTXWBriaCell TherapeuticsN/A$0.06-5.6%N/A-82.2%$0.00N/A0.008High Trading VolumeCALACalithera Biosciences0.5415 of 5 stars$0.00-50.0%N/AN/A$0.00N/A0.0060High Trading VolumeCELUWCelularityN/A$0.03+9.8%N/A+58.5%$0.00$44.59M0.00220Positive NewsGap Down Related Companies and Tools Related Companies 180 Life Sciences Competitors 4D pharma Competitors Ainos Competitors Alvotech Competitors Atlantic Coastal Acquisition Corp. II Competitors Biofrontera Competitors biote Competitors BriaCell Therapeutics Competitors Calithera Biosciences Competitors Celularity Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPRW) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.